@article{c09a73a3f66e438c9018b700dd196166,
title = "Biosimilars: Considerations for payers",
keywords = "Affordability and access, Benefit management, Biosimilars, Managed care, Payers, Pharmacoeconomics",
author = "James Smeeding and Malone, {Daniel C.} and Monica Ramchandani and Bradley Stolshek and Larry Green and Philip Schneider",
note = "Funding Information: Disclosure: Mr. Smeeding reports no competing interests in regard to this article. Dr. Malone has received remuneration for consulting services unrelated to this paper and topic from Amgen Inc., AstraZeneca, Astellas, GlaxoSmithKline, Mallinckrodt, and Sanofi. Mr. Schneider is advisory board chair for the Alliance for Safe Biologic Medicines. Drs. Ramchandani, Stolshek, and Green are employees of Amgen Inc. and own Amgen stock. Editorial support was provided by Miranda Tradewell, Meghan Johnson, and James Balwit from Complete Healthcare Communications, LLC (North Wales, PA), a CHC Group company, whose work was funded by Amgen Inc. under the guidance of Dr. Ramchandani (Amgen Inc.).",
year = "2019",
month = jan,
day = "1",
language = "English (US)",
volume = "44",
pages = "54--63",
journal = "P and T",
issn = "8750-6831",
publisher = "Biomedical Information Corp",
number = "2",
}